Answers are grounded in this paper and cite their sources.
About 90% of people with primary Raynaud’s have visited their general practitioner about it, and ≈50% have been prescribed ≥1 medication. Dear Editor, There is a lack of understanding of health service usage of people with primary RP [i.e. general practitioner (GP) contact and medication prescriptions]. To explore this, we conducted a survey working with Scleroderma and Raynaud’s UK (SRUK) [1], a charity that is dedicated to improving the lives of people with scleroderma and RP. Primary RP is a common condition characterized by episodic constrictions of blood vessels in extremities such as fingers and toes, often triggered by cold environments or stressful situations [2]. Our recent umbrella review [3] found that only one systematic review has investigated the epidemiology of primary RP and there were no studies on primary RP mortality. The authors found a pooled prevalence of 4850 per 100 000 population and a pooled annual incidence of 250 per 100 000 population [4]. Approximately 10 million people live with RP in the UK [5]. The variation in impact on individuals’ lives warrants a deeper understanding of their needs and challenges. Despite the existing research on primary RP [4, 6, 7], patients’ experiences and treatment patterns remains poorly understood in the UK. During April and May 2024, through the SRUK’s website, social media platforms (such as Facebook) and a newsletter, a short questionnaire was posted asking: Do you have primary Raynaud’s (Raynaud’s which is not known to be connected to an underlying health condition such as Scleroderma or Lupus)? Have you ever visited your GP about your Raynaud’s? Has your GP ever prescribed you medication for your Raynaud’s? If you have been prescribed medication for your Raynaud’s, please specify the name of the medication you were prescribed. Ethical approval was not required for this anonymous survey conducted by SRUK of its members. Anonymity was preserved by the collection of no personal identifiable data. Participant consent was implied by their completion of the survey. Of 118 total respondents, 98 indicated they had primary RP (by answering ‘yes’ to question 1). Among the 98 respondents with primary RP, 12 (12.2%) said they regularly visited their GP, 75 (76.5%) indicated they visited their GP once or a few times, but 11 (11.2%) stated they had never visited their GP. A total of 53 (54.1%) respondents reported that they were prescribed medication for their RP when visiting a GP. Those who regularly visited their GP were all prescribed medication. Only 41 of 75 respondents (54.7%) who visited their GP once or a few times were prescribed medication. This implies that the more times respondents visited the GP, the higher the chance that medications were prescribed. The most common medication used to control the symptoms were calcium channel blockers (nifedipine, n = 40; amlodipine, n = 4; felodipine, n = 1; diltiazem, n = 1) (Fig. 1). Other medications prescribed included a phosphodiesterase type 5 inhibitor (sildenafil; n = 8), angiotensin receptor blocker (n = 2), fluoxetine (n = 1), beta-blockers (n = 1), 5-hydroxytryptamine 2 receptor antagonist (n = 1), DMARD (hydroxychloroquine; n = 1) and vasodilator antihypertensive medicine (iloprost; n = 1). Medications used in primary RP Our survey has two key findings. First, 11.2% of people who self-reported primary RP have never gone to see their GP about their condition. As it often runs in families, affected people may use informal routes to gain knowledge to self-manage their condition. However, this has implications for research into primary RP using primary care records, because ≈11% of cases may not be identified. Those not identified include those not prescribed medication for it by their GP, which may potentially include those with less severe symptoms. Second, just over half of the primary RP patients use prescribed medications to manage their condition. The most frequently prescribed medication was nifedipine, which is in line with current medical guidelines [8] for individuals with primary RP. As this report was limited to results of a short, accessible online survey conducted by a patient charity, it did not include sociodemographic or comorbidity information. As little is known about the occurrence of primary RP, further research, especially large population studies at the population level, are needed to provide scientific evidence on the occurrence of primary RP, how it is managed by healthcare providers and its natural history. This information would be used by and to support individuals with primary RP and planners of healthcare services. Data are available upon request. This work was supported by a PhD studentship to A.C. from a benefactor donation to the University of Nottingham. F.P. is funded by a National Institute for Health Research Advanced Fellowship (NIHR300863). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Disclosure statement: The authors have declared no conflicts of interest. We thank the SRUK team for conducting the survey for us. We thank Nick-Jeffries Owen and Sue Farrington (SRUK) for collating the information from the survey for us.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: